Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Opicapone

FDA-approved product (capsule, oral), marketed as Ongentys.

Registered studies
49
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Opicapone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Parkinson disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other dopaminergic agents
FDA pharmacologic class
Catechol-O-Methyltransferase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Opicapone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Opicapone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health

    NCT07257393 · start 2025-12-01

    Registered record
    Registry ID
    NCT07257393
    Conditions
    Idiopathic Parkinsonism
    Interventions
    No Intervention: Observational Cohort
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2026-06-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Parkinsonism
    InterventionNo Intervention: Observational Cohort
    PhaseNot recorded
    Registry statusNot yet recruiting

  • REal-life ON PARKinson's - ITaly (REONPARK-IT)

    NCT07403799 · start 2025-07-08

    Registered record
    Registry ID
    NCT07403799
    Conditions
    Parkinson Disease
    Interventions
    Opicapone 50 mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-07-08
    Completion
    2029-06-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOpicapone 50 mg
    PhaseNot recorded
    Registry statusActive not recruiting

  • Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease

    NCT06432309 · start 2022-07-01

    Registered record
    Registry ID
    NCT06432309
    Conditions
    Parkinson Disease; Effect of Drug
    Interventions
    Opicapone 50 mg; Duodopa
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-07-01
    Completion
    2024-04-25
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Effect of Drug
    InterventionOpicapone 50 mg; Duodopa
    PhaseNot applicable
    Registry statusCompleted

  • eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.

    NCT04990284 · start 2021-11-29

    Registered record
    Registry ID
    NCT04990284
    Conditions
    Parkinson Disease
    Interventions
    Opicapone; L-DOPA/DDCI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-11-29
    Completion
    2023-04-04
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOpicapone; L-DOPA/DDCI
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

    NCT04821687 · start 2021-06-17

    Registered record
    Registry ID
    NCT04821687
    Conditions
    Parkinson Disease
    Interventions
    Ongentys 50mg; Madopar Tab. 125 or Perkin Tab. 25-100mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-06-17
    Completion
    2022-08-18
    Enrolment
    169

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOngentys 50mg; Madopar Tab. 125 or Perkin Tab. 25-100mg
    PhasePhase 4
    Registry statusCompleted

  • OpicApone Sleep dISorder

    NCT04986995 · start 2021-06-09

    Registered record
    Registry ID
    NCT04986995
    Conditions
    Parkinson Disease
    Interventions
    Opicapone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-06-09
    Completion
    2023-03-29
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOpicapone
    PhasePhase 4
    Registry statusCompleted

  • Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

    NCT04978597 · start 2021-05-31

    Registered record
    Registry ID
    NCT04978597
    Conditions
    Parkinson
    Interventions
    Opicapone 50 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-05-31
    Completion
    2024-01-26
    Enrolment
    410

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson
    InterventionOpicapone 50 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Opicapone Treatment Initiation Open-Label Study

    NCT04787965 · start 2021-03-01

    Registered record
    Registry ID
    NCT04787965
    Conditions
    Parkinson Disease
    Interventions
    Opicapone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2022-08-04
    Enrolment
    239

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOpicapone
    PhaseNot recorded
    Registry statusCompleted

  • OpiCapone Effect on Motor Fluctuations and pAiN

    NCT04986982 · start 2021-02-25

    Registered record
    Registry ID
    NCT04986982
    Conditions
    Parkinson Disease
    Interventions
    Opicapone 50 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-02-25
    Completion
    2024-02-16
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOpicapone 50 mg; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

    NCT03959540 · start 2020-04-28

    Registered record
    Registry ID
    NCT03959540
    Conditions
    Parkinson Disease
    Interventions
    Opicapone; Levodopa (L-DOPA) + Standard care
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-04-28
    Completion
    2021-05-11
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOpicapone; Levodopa (L-DOPA) + Standard care
    PhaseNot recorded
    Registry statusCompleted

  • Relative Bioavailability and Bioequivalence of Opicapone

    NCT03820037 · start 2019-03-19

    Registered record
    Registry ID
    NCT03820037
    Conditions
    Parkinson Disease
    Interventions
    Ongentys; BIA 9-1067 (test)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-03-19
    Completion
    2019-06-09
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOngentys; BIA 9-1067 (test)
    PhasePhase 1
    Registry statusCompleted

  • Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

    NCT04265027 · start 2018-02-20

    Registered record
    Registry ID
    NCT04265027
    Conditions
    Parkinson Disease
    Interventions
    50 mg BIA 9 1067; 25 mg BIA9 1067; 50 mg Ongentys; 25 mg Ongentys
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-02-20
    Completion
    2018-07-24
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    Intervention50 mg BIA 9 1067; 25 mg BIA9 1067; 50 mg Ongentys; 25 mg Ongentys
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

    NCT03496870 · start 2018-02-08

    Registered record
    Registry ID
    NCT03496870
    Conditions
    Parkinson Disease
    Interventions
    Opicapone; Carbidopa Levodopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-02-08
    Completion
    2018-07-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOpicapone; Carbidopa Levodopa
    PhasePhase 1
    Registry statusCompleted

  • Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

    NCT03116295 · start 2017-06-20

    Registered record
    Registry ID
    NCT03116295
    Conditions
    Parkinson Disease
    Interventions
    Opicapone (OPC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-06-20
    Completion
    2017-08-28
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionOpicapone (OPC)
    PhasePhase 1
    Registry statusCompleted

  • Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

    NCT03119194 · start 2017-01-27

    Registered record
    Registry ID
    NCT03119194
    Conditions
    Parkinson Disease
    Interventions
    [14C]-BIA 9-1067
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-01-27
    Completion
    2017-04-27
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    Intervention[14C]-BIA 9-1067
    PhasePhase 1
    Registry statusCompleted